Kinase News and Research

RSS

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Cancer remains a leading cause of death worldwide, and the global cancer burden is expected to increase by 70 percent over the next two decades.

14 Jul 2016

Researchers identify PKD1 protein as potential cause for impaired insulin signaling in diabetics

Medication can help trigger the enzyme that kick starts insulin production in the body, but the drugs don't always work for those who are obese or diabetic, and most need to regulate their glucose and insulin levels. That's why a recent discovery made by Rudy Valentine and a team of researchers holds so much promise.

13 Jul 2016

Phase III clinical study of promising prostate cancer drug reveals surprising results

A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any significant improvement in the overall survival of patients compared with the established standard treatment.

12 Jul 2016

Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

A small phase I study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain dopamine and reduced toxic proteins linked to disease progression in patients with Parkinson's disease or dementia with Lewy bodies.

12 Jul 2016

Researchers discover new signaling events that trigger metastasis in ovarian cancer cells

Like pancreatic cancer, cancer of the ovaries is notorious for being discovered at a relatively late stage - after it has spread to other sites in the body. It is not called "the silent killer" for nothing.

11 Jul 2016

Researchers identify potential biomarkers predictive of TKIs response in metastatic renal cancer

A team of CNIO researchers, in collaboration with the Spanish Oncology Genitourinary Group and the University Hospitals Leuven, has discovered various potential biomarkers predictive of tyrosine kinase inhibitors (TKIs) response in metastatic renal cancer.

8 Jul 2016

Researchers identify potential biomarker for Parkinson's disease in biobanked urine samples

For more than five years, urine and cerebral-spinal fluid samples from patients with Parkinson's disease have been locked in freezers in the NINDS National Repository, stored with the expectation they might someday help unravel the still-hidden course of this slow-acting neurodegenerative disease.

6 Jul 2016

TDF reduces vertical HBV transmission

The mother-to-child transmission of hepatitis B virus is reduced with tenofovir disoproxil fumarate treatment during the third trimester in pregnant chronic HBV patients with a high viral load, show the findings of a trial conducted in China.

4 Jul 2016

Immunotherapy in conjunction with drugs could be effective in treating pancreatic cancer

While immune therapy has proven effective in treating certain types of cancer, especially lung cancer and melanoma, tumors of the pancreas remain among the most difficult to treat and, so far, are impervious to immune-based therapies.

4 Jul 2016

ALK fusion variants could influence NSCLC crizotinib response

In non-small-cell lung cancer patients with anaplastic lymphoma kinase rearrangement treated with crizotinib, progression-free survival varies according to the ALK fusion variant.

1 Jul 2016

Researchers engineer revolutionary new approach to combat cancer treatment resistance

Math, biology and nanotechnology are becoming strange, yet effective bed-fellows in the fight against cancer treatment resistance. Researchers at the University of Waterloo and Harvard Medical School have engineered a revolutionary new approach to cancer treatment that pits a lethal combination of drugs together into a single nanoparticle.

24 Jun 2016

Potential therapeutic approaches to combat chronic myeloid leukemia

Chronic myeloid leukemia (CML) develops through chromosomal alterations in blood-forming cells of the bone marrow and usually occurs in older persons. Around 20 percent of adults diagnosed with leukemia suffer from this type of blood cancer.

21 Jun 2016

Researchers identify new myosin kinase that could optimize heart contractions

The heart is the only muscle that contracts and relaxes continuously over a lifetime to pump oxygen-rich blood to the body's organs. Researchers at UT Southwestern Medical Center now have identified a previously unrecognized enzyme that could optimize contraction and lead to new strategies to treat heart failure.

21 Jun 2016

Researchers uncover mechanism of two-in-one sensor protein KdpD

Uptake of potassium by bacteria is regulated by a single protein that senses the concentration of this cation both inside the cell and in the external medium, and controls the expression of the corresponding transport protein accordingly.

20 Jun 2016

Cabozantinib extends advanced RCC overall survival

Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus.

18 Jun 2016

Researchers uncover potential therapeutic benefit of PI3K protein in PanNETs

Researchers from the 'Angiogenesis signaling pathways' research group of the Institute of Biomedical Investigation of Bellvitge, led by Dr. Mariona Graupera, have unveiled the potential therapeutic benefit of a selective inhibitior of the PI3-kinase (PI3K) protein in pancreatic neuroendocrine tumors (PanNETs).

17 Jun 2016

Salvage alloSCT remains option for progressing CML patients

Research demonstrates the continuing role of allogeneic stem cell transplantation as a salvage option for patients with chronic myeloid leukaemia who progress to accelerated phase or blast crisis after tyrosine kinase inhibitor failure.

15 Jun 2016

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Patients with high-risk chronic myeloid leukaemia who undergo allogeneic haematopoietic stem cell transplantation may benefit from continuing with tyrosine kinase inhibitor therapy, US clinicians believe.

15 Jun 2016

Long-term dasatinib findings support first-line use in CML

Final DASISION study findings confirm dasatinib to be an effective, long-term treatment for patients with a new diagnosis of chronic phase-chronic myeloid leukaemia.

15 Jun 2016

PI3K/AKT/mTOR pathway plays key role in prostate tumor growth and progression

The research article - Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy, by Dr Claudio Festuccia and published in Clinical Cancer Drugs, volume 3, issue 1 - discusses experimental and clinical data on the pharmacological inhibition of the Akt/mTOR pathways.

13 Jun 2016

Kinase News and Research

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Researchers identify PKD1 protein as potential cause for impaired insulin signaling in diabetics

Phase III clinical study of promising prostate cancer drug reveals surprising results

Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

Researchers discover new signaling events that trigger metastasis in ovarian cancer cells

Researchers identify potential biomarkers predictive of TKIs response in metastatic renal cancer

Researchers identify potential biomarker for Parkinson's disease in biobanked urine samples

TDF reduces vertical HBV transmission

Immunotherapy in conjunction with drugs could be effective in treating pancreatic cancer

ALK fusion variants could influence NSCLC crizotinib response

Researchers engineer revolutionary new approach to combat cancer treatment resistance

Potential therapeutic approaches to combat chronic myeloid leukemia

Researchers identify new myosin kinase that could optimize heart contractions

Researchers uncover mechanism of two-in-one sensor protein KdpD

Cabozantinib extends advanced RCC overall survival

Researchers uncover potential therapeutic benefit of PI3K protein in PanNETs

Salvage alloSCT remains option for progressing CML patients

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Long-term dasatinib findings support first-line use in CML

PI3K/AKT/mTOR pathway plays key role in prostate tumor growth and progression

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News